{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T04:44:23Z","timestamp":1787805863090,"version":"build-2784847793"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.lungcan.2025.108492","type":"journal-article","created":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T12:15:29Z","timestamp":1741608929000},"page":"108492","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["A phase 1b study of cofetuzumab pelidotin monotherapy in patients with PTK7-expressing recurrent non-small cell lung cancer"],"prefix":"10.1016","volume":"202","author":[{"given":"Byoung Chul","family":"Cho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jair","family":"Bar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Schaefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6928-357X","authenticated-orcid":false,"given":"Kiyotaka","family":"Yoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alona","family":"Zer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mor","family":"Moskovitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se-Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6099-4236","authenticated-orcid":false,"given":"Victor","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"de Miguel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Okuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joo-Hang","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5276-9896","authenticated-orcid":false,"given":"Chun-Hui","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Peguero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Ansell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6879-6557","authenticated-orcid":false,"given":"Carla","family":"Biesdorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabih","family":"Saab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7142-2444","authenticated-orcid":false,"given":"Kevin J.","family":"Freise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3223-648X","authenticated-orcid":false,"given":"David","family":"Ramies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2824-4763","authenticated-orcid":false,"given":"Edwin E.","family":"Jeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Ross","family":"Camidge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2025.108492_b0005","unstructured":"American Cancer Society, Cancer Facts & Figures 2023. https:\/\/www.cancer.org\/research\/cancer-facts-statistics\/all-cancer-facts-figures\/2023-cancer-facts-figures.html, 2023 (accessed 11 September 2024)."},{"key":"10.1016\/j.lungcan.2025.108492_b0010","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.lungcan.2025.108492_b0015","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13045-020-00881-7","article-title":"Emerging therapeutic agents for advanced non-small cell lung cancer","volume":"13","author":"Chen","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.lungcan.2025.108492_b0020","doi-asserted-by":"crossref","first-page":"497","DOI":"10.6004\/jnccn.2022.0025","article-title":"Non-small cell lung cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"20","author":"Ettinger","year":"2022","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"10.1016\/j.lungcan.2025.108492_b0025","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1038\/onc.2009.196","article-title":"Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs","volume":"28","author":"Burris","year":"2009","journal-title":"Oncogene"},{"key":"10.1016\/j.lungcan.2025.108492_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2024.05.293","article-title":"Real-world outcomes in patients with EGFR wildtype non-squamous locally advanced\/metastatic NSCLC receiving second- or third-line docetaxel: pooled analysis from LUMINATE-01","volume":"19","author":"Girard","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2025.108492_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102669","article-title":"Real-world (RW) post-progression outcomes and treatment (tx) patterns after first-line (1L) immuno-oncology (IO) regimens in patients (pts) with metastatic (m) NSCLC: CORRELATE","volume":"9","author":"Liu","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.lungcan.2025.108492_b0040","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13045-021-01035-z","article-title":"Antibody-drug conjugates in solid tumors: a look into novel targets","volume":"14","author":"Criscitiello","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.lungcan.2025.108492_b0045","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.lungcan.2021.11.016","article-title":"Antibody drug conjugates in non-small cell lung cancer: An emerging therapeutic approach","volume":"163","author":"Marks","year":"2022","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2025.108492_b0050","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41698-022-00338-9","article-title":"Antibody-drug conjugates in lung cancer: dawn of a new era?","volume":"7","author":"Coleman","year":"2023","journal-title":"NPJ Precis. Oncol."},{"key":"10.1016\/j.lungcan.2025.108492_b0055","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3389\/fcell.2017.00031","article-title":"PTK7 Faces the Wnt in Development and Disease","volume":"5","author":"Berger","year":"2017","journal-title":"Front. Cell Dev. Biol"},{"key":"10.1016\/j.lungcan.2025.108492_b0060","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aag2611","article-title":"A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions","volume":"9","author":"Damelin","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.lungcan.2025.108492_b0065","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3390\/cancers8070068","article-title":"Ptk7 and Mcc, unfancied components in non-canonical Wnt signaling and cancer","volume":"8","author":"Dunn","year":"2016","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.lungcan.2025.108492_b0070","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1158\/0008-5472.CAN-13-2775","article-title":"A meta-analysis of lung cancer gene expression identifies PTK7 as a survival gene in lung adenocarcinoma","volume":"74","author":"Chen","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.lungcan.2025.108492_b0075","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.1158\/1078-0432.CCR-20-3757","article-title":"First-in-human study of PF-06647020 (cofetuzumab pelidotin), an antibody-drug conjugate targeting protein tyrosine kinase 7, in advanced solid tumors","volume":"27","author":"Maitland","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2025.108492_b0080","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s10637-017-0520-6","article-title":"Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads","volume":"36","author":"Masters","year":"2018","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.lungcan.2025.108492_b0085","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2025.108492_b0090","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"ARittmeyer","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2025.108492_b0095","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1158\/1535-7163.MCT-23-0164","article-title":"MTX-13, a novel PTK7-directed antibody-drug conjugate with widened therapeutic index shows sustained tumor regressions for a broader spectrum of PTK7-positive tumors","volume":"22","author":"Kong","year":"2023","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.lungcan.2025.108492_b0100","first-page":"1406","article-title":"1406 A novel PTK7-directed antibody-drug conjugate (ADC) PRO1107 demonstrated broad antitumor activity with a promising safety profile in preclinical models","volume":"11","author":"Xiao","year":"2023","journal-title":"J. Immunother. Cancer"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225003848?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225003848?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T16:22:10Z","timestamp":1744129330000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500225003848"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":20,"alternative-id":["S0169500225003848"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108492","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase 1b study of cofetuzumab pelidotin monotherapy in patients with PTK7-expressing recurrent non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108492","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"108492"}}